SEC Form 4 · accession 0001493152-26-035634
HCW Biologics Inc. · HCWB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hing C Wong
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Jul 29, 2026
Accepted (ET)
Jul 31, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001828673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 29, 2026 | P | 23,210 | $2.585 | A | 125,845 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.